Biopharmaceutical company developing therapies for rare neurological disorders.
Ovid Therapeutics Inc., headquartered in New York, is a pioneering biopharmaceutical company dedicated to developing transformative treatments for individuals and families affected by neurological disorders across the United States. Established in 2014, Ovid focuses on advancing innovative therapies that address significant unmet medical needs.
Central to Ovid's pipeline is OV101, currently undergoing Phase 2A clinical trials for fragile X syndrome, a developmental condition characterized by intellectual disabilities and behavioral challenges. Additionally, the company is developing OV329, a promising GABA aminotransferase inhibitor aimed at treating seizures associated with tuberous sclerosis complex and infantile spasms. OV350, another key development, represents a novel small molecule therapy targeting epilepsies.
Complementing these efforts, Ovid is also pioneering OV882, a cutting-edge short hairpin RNA gene therapy designed to tackle angelman syndrome, a genetic disorder causing developmental delays and neurological problems. Furthermore, OV815 is being developed to address neurological disorders associated with kinesin-family proteins.
In addition to its robust internal research programs, Ovid Therapeutics has established strategic collaborations and license agreements with industry leaders such as Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, along with Marinus Pharmaceuticals, Inc. These partnerships enhance Ovid's capabilities in accelerating the development and delivery of groundbreaking treatments to patients in need.